Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 28, 2026
Perspective Therapeutics, Inc. (CATX)
A forensic read on Perspective Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-4.3
Altman Z-score
Watch
Earnings quality
5
Forensic signals
-41.8%
ROE
$347M
Market cap
Perspective Therapeutics, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -4.3, placing it in the Distress zone. 5 forensic signals were flagged in its latest SEC filings, led by inventory days.
What the filings flag
73dInventory days.Days inventory outstanding moved from 52 to 73 FY2020→FY2021 (against cost of goods sold; inventory +52% vs +8% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
-43%Return on invested capital.Return on invested capital is -43% and slipping from -20% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+87.9%/yrShare-count dilution.Diluted share count changed +176% over the last 2 years to FY2025 (+87.9%/yr). The count is GROWING — existing holders are being diluted. That's ~87.9% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~176%.
261% of revStock-based comp load.Stock-based compensation ran 261% of revenue in FY2023 — about $0.14 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
$24MGoodwill impairments.Took $24M of goodwill writedowns across 1 year(s) (FY2024 ($24M)). Writedowns mean past acquisitions underperformed what was paid for them — worth weighing on capital-allocation skill.
Key fundamentals
Net Margin-3243.2%
Debt / Equity0.01x
Free Cash Flow$-95.2M
Latest Revenue$1.4M
Return on Equity-49.8%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Perspective Therapeutics, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about CATX's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown